The first clinical trials which were performed using Nesiritide (recombinant human BNP), highlighted positive hemodynamic and clinical effects in patients with acute heart failure, but also severe adverse effects, such as hypotension, renal failure and a higher mortality rate in the group of BNP-treated patients [28]. This evidence concerns the gene NPPB and Renal insufficiency.